Revisions are highlighted with new image

Alberta Health Services	OTHER NAMES:	sotrovimab
Monoclonal antibody, Antiviral agent		

ROUTE of ADMINISTRATION	INTRAVENOUS			SUBCUTANEOUS		IM
	Direct IV	Intermittent	Continuous	Injection	Infusion	
	NO	YES [1]	NO	NO	NO	NO

REQUIRED EDUCATION, EQUIPMENT OR MONITORING

1. Administer with a 0.2 or 0.22 micron filter.

INDICATIONS

- Mild to moderate Coronavirus disease 2019 (COVID-19) at high risk of progressing to hospitalization or death.
- Refer to AHS Provincial Drug Formulary for restrictions and more information.

CONTRAINDICATIONS / CAUTIONS

CONTRAINDICATIONS

- Hypersensitivity to sotrovimab or excipients.

NEONATES - DOSAGE

Safety and efficacy of sotrovimab in neonates has not been established, therefore dosages are not available.

INFANTS / CHILDREN - DOSAGE

- Safety and efficacy of sotrovimab in patients younger than 12 years of age or weighing less than 40 kg has not been established, therefore dosages are not available.
- Administer as soon as possible after onset of symptoms and a positive COVID-19 test.

COVID-19:

- 12 years old or more and 40 kg or more:
  - IV: 500 mg as a single dose.

INFANTS/CHILDREN

RENAL FAILURE

- Dosage adjustments are not required for renal impairment.

INFANTS/CHILDREN

HEPATIC FAILURE

- Dosage adjustments are not provided by the manufacturer (has not been studied). Use with caution.

INFANTS/CHILDREN

INFANTS / CHILDREN - ADMINISTRATION / DILUTION

- If the diluted solution was refrigerated, equilibrate at room temperature for 15 minutes prior to administration.
- Administer with a 0.2 or 0.22 micron filter.

INTERMITTENT IV INFUSION - Infants / Children

- Rate:
  - Administer over 60 minutes.

INFANTS/CHILDREN

- Concentration:
  - Remove vials from refrigerator and allow to equilibrate to room temperature for approximately 15 minutes before preparation.
  - Gently swirl the vial several times before use. Do not shake.
  - Dilute dose in 100 mL of NS.
  - Following preparation, gently rock IV bag by hand approximately 3 to 5 times to mix. Do not invert the infusion bag.

ADULTS - DOSAGE

- Safety and efficacy of sotrovimab in patients younger than 12 years of age or weighing less than 40 kg has not been established, therefore dosages are not available.
- Administer as soon as possible after onset of symptoms and a positive COVID-19 test.

COVID-19:

- 40 kg or more:
  - IV: 500 mg as a single dose.

ADULTS

RENAL FAILURE

- Dosage adjustments are not required for renal impairment.

ADULTS

HEPATIC FAILURE

- Dosage adjustments are not provided by the manufacturer (has not been studied). Use with caution.

ADULTS

ADULTS - ADMINISTRATION / DILUTION

- If the diluted solution was refrigerated, equilibrate at room temperature for 15 minutes prior to administration.
- Administer with a 0.2 or 0.22 micron filter.

INTERMITTENT IV INFUSION - Adults

- Rate:
  - Administer over 60 minutes.

ADULTS

- Concentration:
  - Remove vials from refrigerator and allow to equilibrate to room temperature for approximately 15 minutes before preparation.
  - Gently swirl the vial several times before use. Do not shake.
  - Dilute dose in 100 mL of NS.
  - Following preparation, gently rock IV bag by hand approximately 3 to 5 times to mix. Do not invert the infusion bag.

ADVERSE EFFECTS

- **Less frequent (1 to 10%):**
  - Rash, diarrhea.
  - Infusion-related reactions including fever, dyspnea, chills, bronchospasm, rash, pruritus, and dizziness.
- **Rare (less than 1%):**
  - Nausea, headache, and dyspnea.
  - Anaphylaxis.

CLINICAL IMPLICATIONS

- Assess for hypersensitivity/ infusion reactions during infusion and monitor for at least 1 hour after infusion is complete.
- If an infusion-related reaction occurs, slow or stop the infusion. Administer supportive care as required.

PRODUCT DESCRIPTION / RECONSTITUTION / STABILITY

PRODUCT DESCRIPTION

- Available as 62.5 mg/mL injection.
- Refrigerate unopened products and protect from light. Do not shake.
- Sotrovimab may contain polysorbate 80 (Tween).

IV SOLUTION STABILITY (Please note that stability information does not apply to parenteral products mixed by Pharmacy).

- NS: Stable for 4 hours at room temperature or 24 hours refrigerated.

COMPATIBILITY

- **The parenteral monographs are not meant to be a comprehensive source of compatibility information**. For the most current and complete listing of compatibility data, please consult Micromedex or Lexicomp.
- Drug IV compatibility is dependent on a number of factors including tested concentrations, diluents and storage conditions. See monograph template for more detailed information.
- Compatibility of **MORE THAN TWO** drugs in the same line or container **may NOT** be inferred from any information presented in the following intravenous compatibility charts.

No compatibility studies have been done. Do NOT mix with other drugs in the same IV line.